MetLife Investment Management’s Tourmaline Bio TRML Stock Holding History

MetLife Investment Management’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,394	Closed	-$497K	–	2874
2025 Q3	$497K	Sell	10,394 -3,159	-23%	-$87.6K	﹤0.01%	1808
2025 Q2	$217K	Hold	13,553	–	–	﹤0.01%	2148
2025 Q1	$206K	Sell	13,553 -333	-2%	-$5.34K	﹤0.01%	2183
2024 Q4	$282K	Hold	13,886	–	–	﹤0.01%	2120
2024 Q3	$357K	Buy	+13,886	New	+$232K	﹤0.01%	1971
2022 Q3	–	Sell	-1,392	Closed	-$62.8K	–	2839
2022 Q2	$62.8K	Buy	+1,392	New	+$110K	﹤0.01%	2789
2022 Q1	–	Sell	-976	Closed	-$149K	–	2772
2021 Q4	$149K	Buy	+976	New	+$144K	﹤0.01%	2240

MetLife Investment Management's TRML Position: Q4 2025 in Review

MetLife Investment Management sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 10,394 shares — an estimated $497K sold.

MetLife Investment Management first reported a position in TRML in Q4 2021 and held it in 7 quarters. The position peaked at $497K in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

MetLife Investment Management reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
MetLife Investment Management sold 10,394 Tourmaline Bio shares in Q4 2025, an estimated $497K.
MetLife Investment Management first reported a position in Tourmaline Bio in Q4 2021 and held it in 7 quarters.
MetLife Investment Management's Tourmaline Bio position peaked at $497K in Q3 2025.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on MetLife Investment Management's 13F filing for Q4 2025, filed 12 Feb 2026.